Abstract: [Problem] To provide a complex comprising a ligand, spacer, and peptide linker useful in internal diagnostics and internal radiation therapy that uses an anti-human MUC1 antibody Fab fragment the binding activity of which is not weakened even by labeling by a metal, fluorescent dye, or the like. [Solution] A complex comprising a 3-arm DOTA, a specific spacer, a specific peptide linker, and a biomolecule containing an anti-human MUC1 antibody Fab fragment can be used as a diagnostic composition and/or pharmaceutical composition the binding activity of which is not weakened even by labeling by a metal, fluorescent dye, or the like.
| # | Name | Date |
|---|---|---|
| 1 | 202147034891-FORM 3 [12-09-2023(online)].pdf | 2023-09-12 |
| 1 | 202147034891-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [03-08-2021(online)].pdf | 2021-08-03 |
| 2 | 202147034891-FORM 3 [28-11-2022(online)].pdf | 2022-11-28 |
| 2 | 202147034891-STATEMENT OF UNDERTAKING (FORM 3) [03-08-2021(online)].pdf | 2021-08-03 |
| 3 | 202147034891-SEQUENCE LISTING(PDF) [03-08-2021(online)].pdf | 2021-08-03 |
| 3 | 202147034891-FORM 3 [26-10-2022(online)].pdf | 2022-10-26 |
| 4 | 202147034891-SEQUENCE LISTING [03-08-2021(online)].txt | 2021-08-03 |
| 4 | 202147034891-FORM 18 [25-10-2022(online)].pdf | 2022-10-25 |
| 5 | 202147034891-PROOF OF RIGHT [03-08-2021(online)].pdf | 2021-08-03 |
| 5 | 202147034891-Correspondence_Form1_02-08-2022.pdf | 2022-08-02 |
| 6 | 202147034891-PRIORITY DOCUMENTS [03-08-2021(online)].pdf | 2021-08-03 |
| 6 | 202147034891-Correspondence_GPA_13-07-2022.pdf | 2022-07-13 |
| 7 | 202147034891-FORM 3 [20-01-2022(online)].pdf | 2022-01-20 |
| 7 | 202147034891-FORM 1 [03-08-2021(online)].pdf | 2021-08-03 |
| 8 | 202147034891.pdf | 2021-10-19 |
| 8 | 202147034891-DRAWINGS [03-08-2021(online)].pdf | 2021-08-03 |
| 9 | 202147034891-DECLARATION OF INVENTORSHIP (FORM 5) [03-08-2021(online)].pdf | 2021-08-03 |
| 9 | 202147034891-FORM-26 [12-08-2021(online)].pdf | 2021-08-12 |
| 10 | 202147034891-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [03-08-2021(online)].pdf | 2021-08-03 |
| 10 | 202147034891-COMPLETE SPECIFICATION [03-08-2021(online)].pdf | 2021-08-03 |
| 11 | 202147034891-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [03-08-2021(online)].pdf | 2021-08-03 |
| 11 | 202147034891-COMPLETE SPECIFICATION [03-08-2021(online)].pdf | 2021-08-03 |
| 12 | 202147034891-DECLARATION OF INVENTORSHIP (FORM 5) [03-08-2021(online)].pdf | 2021-08-03 |
| 12 | 202147034891-FORM-26 [12-08-2021(online)].pdf | 2021-08-12 |
| 13 | 202147034891-DRAWINGS [03-08-2021(online)].pdf | 2021-08-03 |
| 13 | 202147034891.pdf | 2021-10-19 |
| 14 | 202147034891-FORM 1 [03-08-2021(online)].pdf | 2021-08-03 |
| 14 | 202147034891-FORM 3 [20-01-2022(online)].pdf | 2022-01-20 |
| 15 | 202147034891-Correspondence_GPA_13-07-2022.pdf | 2022-07-13 |
| 15 | 202147034891-PRIORITY DOCUMENTS [03-08-2021(online)].pdf | 2021-08-03 |
| 16 | 202147034891-Correspondence_Form1_02-08-2022.pdf | 2022-08-02 |
| 16 | 202147034891-PROOF OF RIGHT [03-08-2021(online)].pdf | 2021-08-03 |
| 17 | 202147034891-FORM 18 [25-10-2022(online)].pdf | 2022-10-25 |
| 17 | 202147034891-SEQUENCE LISTING [03-08-2021(online)].txt | 2021-08-03 |
| 18 | 202147034891-SEQUENCE LISTING(PDF) [03-08-2021(online)].pdf | 2021-08-03 |
| 18 | 202147034891-FORM 3 [26-10-2022(online)].pdf | 2022-10-26 |
| 19 | 202147034891-STATEMENT OF UNDERTAKING (FORM 3) [03-08-2021(online)].pdf | 2021-08-03 |
| 19 | 202147034891-FORM 3 [28-11-2022(online)].pdf | 2022-11-28 |
| 20 | 202147034891-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [03-08-2021(online)].pdf | 2021-08-03 |
| 20 | 202147034891-FORM 3 [12-09-2023(online)].pdf | 2023-09-12 |